Abstract: Quaternion-based machine learning algorithms have emerged as a promising candidate for four dimensional (4D) signal processing, which utilize 4D signal dimensions’ correlations for ...

On July 4, 2026, Vitalik Buterin published the most consequential Ethereum protocol document in four years: an updated "Lean Ethereum" strawmap that commits the world's second-largest blockchain to ...

A recursive relation, relating leading principal minors, is developed for the determinant of a pentadiagonal matrix. A numerical example is included to indicate its use in calculating eigenvalues.

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Earnings call Recursion Pharmaceuticals delivered strong operational progress with a 30% YoY reduction in operating expenses and an extended cash runway into early 2028. Clinical momentum was ...

Researchers have developed new algorithms to enhance the reliability of data center networks (DCNs) by constructing ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

An oft-mentioned advantage of ALGOL over FORTRAN is the recursion capability of the former. FORTRAN adherents often belittle this advantage by claiming that all recursive relations can be reduced to ...

Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...